New drug trial aims to unleash immune system against skin cancer
Disease control
Ongoing
This early-stage study is testing a new oral drug called SX-682 in people with advanced melanoma that has spread. The goal is to see if SX-682 can safely block certain cells that shield the tumor, allowing the patient's own immune system, boosted by an existing immunotherapy drug…
Phase: PHASE1 • Sponsor: Syntrix Biosystems, Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC